

What is claimed is:

1. A nucleic acid encoding a truncated NEBR1  
transcriptional repressor consisting essentially of amino acids  
1-300 of SEQ ID NO: 2.

2. A nucleic acid encoding a truncated NEBR1  
transcriptional repressor consisting essentially of amino acids  
1-241 of SEQ ID NO: 2.

3. A nucleic acid encoding a truncated NEBR1  
transcriptional repressor consisting essentially of amino acids  
1-115 of SEQ ID NO:2.

4. A vector comprising the nucleic acid of claims 1, 2, or  
3.

5. A host cell comprising a vector as claimed in claim 4.

6. A host cell as claimed in claim 5, wherein said host  
cell is a macrophage.

7. A truncated NEBR1 transcriptional repressor protein  
selected from the group consisting of:

- a) amino acids 1-300 of SEQ ID NO: 2;
- b) amino acids 1-241 of SEQ ID NO: 2; and
- c) amino acids 1-115.

8. An antibody immunologically specific for NEBR1.

9. An antibody as claimed in claim 8, wherein said antibody  
is polyclonal.

10. An antibody as claimed in claim 8, wherein said antibody is monoclonal.

11. A method for identifying NEBR1 expression in a biological sample, comprising contacting said sample with a detectably labeled antibody immunologically specific for NEBR1 and determining the presence of NEBR1 expression as a function of the amount of detectably labeled antibody bound by the sample relative to control cells.

12. A method as claimed in claim 11, wherein said detectable label is selected from the group consisting of fluorescein, texas red and rhodamine.

13. A method as claimed in claim 11, wherein said biological sample is selected from the group consisting of brain tissue, polymorphonuclear blood mononucleocytes, macrophages and CD4+ T cells.

14. A method for treating HIV infection comprising administering a therapeutic amount of NEBR1 to HIV infected cells in a patient in need thereof.

15. A method as claimed in claim 14, further comprising the administration of at least one antiviral agent selected from the group consisting of reverse transcriptase (RT)inhibitors, non-nucleoside inhibitors, and HIV-protease inhibitors.